JP2023507799A5 - - Google Patents

Info

Publication number
JP2023507799A5
JP2023507799A5 JP2022538229A JP2022538229A JP2023507799A5 JP 2023507799 A5 JP2023507799 A5 JP 2023507799A5 JP 2022538229 A JP2022538229 A JP 2022538229A JP 2022538229 A JP2022538229 A JP 2022538229A JP 2023507799 A5 JP2023507799 A5 JP 2023507799A5
Authority
JP
Japan
Prior art keywords
cancer
product according
pharmaceutical product
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507799A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065411 external-priority patent/WO2021127046A1/en
Publication of JP2023507799A publication Critical patent/JP2023507799A/ja
Publication of JP2023507799A5 publication Critical patent/JP2023507799A5/ja
Pending legal-status Critical Current

Links

JP2022538229A 2019-12-20 2020-12-16 組み合わせ Pending JP2023507799A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US62/952,042 2019-12-20
US202063009754P 2020-04-14 2020-04-14
US63/009,754 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (2)

Publication Number Publication Date
JP2023507799A JP2023507799A (ja) 2023-02-27
JP2023507799A5 true JP2023507799A5 (enExample) 2023-12-25

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538229A Pending JP2023507799A (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230042653A1 (enExample)
EP (1) EP4069224A4 (enExample)
JP (1) JP2023507799A (enExample)
KR (1) KR20220119428A (enExample)
CN (1) CN115103673A (enExample)
AU (1) AU2020408698A1 (enExample)
BR (1) BR112022012286A2 (enExample)
CA (1) CA3165477A1 (enExample)
IL (1) IL294084A (enExample)
MX (1) MX2022007624A (enExample)
TW (1) TW202135810A (enExample)
WO (1) WO2021127046A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CN101970440A (zh) * 2007-11-28 2011-02-09 先灵公司 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
EP2477628B1 (en) * 2009-09-15 2014-08-20 Merck Sharp & Dohme Corp. Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
RS56680B1 (sr) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US11932650B2 (en) * 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
SG11202003974XA (en) * 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
KR20220044528A (ko) * 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제

Similar Documents

Publication Publication Date Title
JP2023508325A5 (enExample)
Šarenac et al. Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease
JP2023507797A5 (enExample)
Richie et al. Breast cancer: a review of the literature
Fernandez-Pineda et al. Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital
Roche et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial
JP2023507799A5 (enExample)
Pontrelli et al. Primary vaginal adenosarcoma with sarcomatous overgrowth arising in recurrent endometriosis: feasibility of laparoscopic treatment and review of the literature
JP2018520182A (ja) 乳房障害を処置するための経乳頭方法及び組成物
Malik et al. Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
CN100408036C (zh) 阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途
Yousefnia Breast cancer, subtypes, risk factors, and treatment
Soh et al. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women
Fan et al. Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer
Goodman Primary vaginal cancer
Ahmad et al. Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice
Cetin et al. Squamous cell carcinoma of the vagina
Zin et al. Primary Vaginal Melanoma–Cytohistological Correlates and Literature Reviews
Saurborn et al. Rare Presentation of Metastatic Breast Cancer Involving the Peritoneal Cavity: Two Cases Arising From Stage 0/1 Disease
Benjamin et al. First report of primary fallopian tube cancer diagnosed by liquid-based cytology in an asymptomatic woman.
Suresh Diagnostic and Management Challenges of Endometrial Tumours in Developing Countries
van der Veldt et al. Metastatic renal cell cancer in a 20-year-old pregnant woman
Chakalova et al. Endometrial carcinoma in a 20 years old or less female: a rare presentation of four cases
Yan et al. Radiotherapy for Postsurgical Vaginal Recurrences of Cervical Squamous Cell Carcinoma: Analysis of Dosing and Prognosis
Arslan et al. Case Report Isolated Uterine Metastasis of Invasive Ductal Carcinoma